ÂÜÀòÂÒÂ×

Matthew Foy is a seasoned professional in the biotechnology and investment sectors, currently serving as a Partner at SR One, a prominent trans-Atlantic biotech venture capital firm since June 2011. In addition to this role, Matthew holds various positions including Investor Director at Econic Biosciences and Xap Therapeutics, and Board Member at Fore Biotherapeutics and PULMOCIDE LIMITED. Matthew's experience spans consulting and seed investment with PRESS London and supporting emerging artists as a Young Artist Patron with Art Patron. Matthew has a strong educational background in Biological Sciences from the University of Oxford, coupled with executive training in Entrepreneurship and Strategy from London Business School. Through strategic investments and board engagements, Matthew Foy is committed to advancing innovative solutions in healthcare and the arts.